Myelin synthesis pathway

The "myelin synthesis pathway" refers broadly to a set of interconnected cellular and molecular processes responsible for generating myelin sheaths around neuronal axons. This is not a single molecule or canonical drug target but rather encompasses numerous enzymes, structural proteins, signaling pathways, and cell types—primarily oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system—that coordinate myelination. Key molecular players include major structural proteins such as proteolipid protein (PLP) and myelin basic protein (MBP), lipid biosynthetic enzymes, and regulatory signaling cascades like PI3K-Akt-mTOR that drive protein translation necessary for sheath growth[1][3][6]. Disruption of this complex process underlies demyelinating diseases such as multiple sclerosis. While some receptors within these pathways—such as M1 muscarinic acetylcholine receptor—have been validated as therapeutic targets for promoting remyelination[2][4], "myelin synthesis pathway" itself is too broad to be considered a single therapeutic target. Note: "Myelin synthesis pathway" does not refer to a discrete molecule or receptor but rather an entire biological process involving many components. For structured data extraction or drug discovery purposes, it is necessary to specify individual molecular entities within this process—for example, "M1 muscarinic acetylcholine receptor," "proteolipid protein," or "Akt-mTOR signaling." As written, this entry should be flagged as incorrect if used where a canonical target name is required.

Other names

Myelin biosynthesis pathwayMyelination pathwayPathways regulating myelin synthesis

Not applicable; mechanisms relate to modulation of specific molecular targets within the pathway, e.g., M1 muscarinic acetylcholine receptor antagonism promotes oligodendrocyte differentiation and remyelination